Lithium gluconate (drug) glyceryl triacetate gta (drug) (DrugBank: Glyceryl triacetate)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
307 | Canavan disease | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00657748 (ClinicalTrials.gov) | September 2009 | 9/4/2008 | Lithium and Acetate for Canavan Disease | Evaluation of the Tolerance and Efficiency of a Combined Oral Therapy With Lithium and GTA in Patients With Canavan Disease | Canavan Disease;Infantile;Deficiency Disease;Aspartoacylase;Leukodystrophy, Spongiform | Drug: Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug) | Assistance Publique - Hôpitaux de Paris | European Leukodystrophy Association;European Leukodystrophy Association | Withdrawn | 1 Year | 15 Years | Both | 0 | Phase 2 | France |